Biofrontera (STU:AI10) Quality Rank


STU:AI10 Biofrontera Inc STU:AI10
43 GF Score
Price €8.06
GF Value €3.96
! 7 Warning Signs
View Full Analysis

What is Biofrontera Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Biofrontera Quality Rank Related Terms

STU:AI10
43GF Score
Biofrontera Inc STU:AI10
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera (STU:AI10) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of €8.06 is trading 103.5% above its estimated GF Value™ of €3.96.

Key valuation signals for STU:AI10:

  • Quality Rank:
  • GF Value™: €3.96 vs. price of €8.06 (103.5% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the STU:AI10 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Other Exchanges BFRI:USA
Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
43GF Score

Get the complete analysis for STU:AI10

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.06
Price
€3.96
GF Value